1. Home
  2. CTS vs PGEN Comparison

CTS vs PGEN Comparison

Compare CTS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$60.23

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$5.34

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
PGEN
Founded
1896
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
CTS
PGEN
Price
$60.23
$5.34
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.33
AVG Volume (30 Days)
350.7K
5.1M
Earning Date
04-29-2026
05-13-2026
Dividend Yield
0.29%
N/A
EPS Growth
15.87
N/A
EPS
0.59
N/A
Revenue
$541,318,000.00
$230,981,000.00
Revenue This Year
$5.55
$1,115.92
Revenue Next Year
$5.00
$81.04
P/E Ratio
$103.93
N/A
Revenue Growth
4.95
N/A
52 Week Low
$36.03
$1.54
52 Week High
$69.55
$6.04

Technical Indicators

Market Signals
Indicator
CTS
PGEN
Relative Strength Index (RSI) 45.89 55.58
Support Level $54.75 $5.20
Resistance Level $62.02 $5.47
Average True Range (ATR) 1.98 0.29
MACD -0.06 -0.06
Stochastic Oscillator 45.12 54.31

Price Performance

Historical Comparison
CTS
PGEN

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: